KRAS and neoplasm: Here, we showed how deltarasin functions to abrogate a mutant KRAS-initiated in vivo inflammatory loop of tumor-derived CCL2 and myeloid-secreted IL-1β by downregulating the IL1R1 expression of KRAS-mutant tumor cells and thereby abolishing their receptivity to myeloid IL-1β signals.